PARP1 and osteosarcoma: In addition, when considering the recent report that the mutation signature of osteosarcomas is reminiscent of BRCA-deficient tumors [19] and the start of clinical use of PARP inhibitors in human cancers [20], it is important to evaluate the anti-cancer effects of PARP inhibition in osteosarcomas.